Jacobsen Pharma Consultancy A/S has been acquired by PharmaLex GmbH
PharmaLex GmbH, a portfolio company of the funds advised by AUCTUS, has acquired pharma services provider Jacobsen Pharma Consultancy A/S (Jacobsen Pharma). PharmaLex GmbH continues its expansion strategy, opening up the Scandinavian pharmaceutical market. Financial details of this transaction have not been disclosed.
Jacobsen Pharma is a privately owned Danish company offering comprehensive consultancy services to the pharmaceutical and associated industries, from early product development right through to licensing and beyond. Jacobsen Pharma is specialized in providing regulatory affairs, development management and project management support.
In October 2014, funds advised by AUCTUS acquired a controlling stake in YES Pharma Services, a highly specialized service provider in the fields of regulatory affairs, product development and drug safety for pharmaceuticals, medical devices and cosmetics. AUCTUS invested in a growth market at the interface between the pharmaceutical industry and business process outsourcing. After acquiring the company, a rapid growth path was taken with the acquisitions of ActioMed and Wainwright in the second half of 2015, which found its peak in the merger with PharmaLex at the end of 2015.
Oaklins' team in Denmark was mandated to assist the owner in the divestment of Jacobsen Pharma to PE-backed PharmaLex GmbH.
Anette Jacobsen
CEO, Jacobsen Pharma Consultancy A/S
Talk to the deal team
Related deals
Zephyr Group has acquired PK OEM Parts
Zephyr Group has acquired PK OEM Parts. With the entry of PK OEM Parts, Zephyr Group aims to achieve a consolidated turnover of approximately US$65 million in 2023. The acquisition will allow an increase in the services and product range offered to customers by leveraging the group’s know-how and logistical capabilities. Furthermore, the acquisition represents a step forward in the growth and consolidation strategy that Zephyr Group started in 2018 with the acquisition of Spanish competitor SKV.
Learn moreBaird Capital invests in Freemarket
Baird Capital has completed a growth capital investment in Freemarket. The investment supports Freemarket’s continuing fast growth and international expansion, as well as providing a partial cash-out to existing shareholders.
Learn moreStrahinjcica has been acquired by Studenac
The owner of Strahinjcica has sold the company to Studenac.
Learn more